Votrient (pazopanib) 200 mg film-coated tablets, 30 tablets — original (Novartis) Treatment of advanced renal cell carcinoma (RCC) Delivery of medications from Europe and beyond within 4-5 days, compliance with storage conditions, payment upon receipt

Votrient (Pazopanib) is an oral antineoplastic agent and tyrosine kinase inhibitor.

Votrient (Pazopanib) is used to treat advanced renal cell carcinoma (RCC) and advanced soft tissue sarcoma (excluding gastrointestinal stromal tumors and liposarcoma) in patients who have previously received chemotherapy.

Pazopanib is an inhibitor of multiple tyrosine kinases, including endothelial growth factor receptor tyrosine kinases 1, 2, and 3 (VEGFR-1, VEGFR-2, and VEGFR-3), platelet-derived growth factor receptor alpha and beta (PDGFR-? and PDGFR-?), and fibroblast growth factor receptor 1 and 3 (FGFR-1 and -3).